Lauro Bucchi, Fabiola Giudici, Federica Toffolutti, Angela De Paoli, Silvia Mancini, Mario Preti, Gemma Gatta, Stefano Ferretti, Emanuele Crocetti, Anna Rita Fiore, Ettore Bidoli, Adele Caldarella, Fabio Falcini, Alessio Gili, Francesco Cuccaro, Maria Letizia Gambino, Claudia Casella, Rossella Cavallo, Margherita Ferrante, Enrica Migliore, Giuliano Carrozzi, Antonino Musolino, Walter Mazzucco, Cinzia Gasparotti, Mario Fusco, Paola Ballotari, Giuseppe Sampietro, Lucia Mangone, William Mantovani, Giuseppe Cascone, Michael Mian, Federica Manzoni, Maria Teresa Pesce, Rocco Galasso, Francesca Bella, Pietro Seghini, Anna Clara Fanetti, Daniela Piras, Pasquala Pinna, Diego Serraino, Stefano Guzzinati, Luigino Dal Maso
{"title":"Prevalence and indicators of cure of Italian women with vulvar squamous cell carcinoma: A population-based study.","authors":"Lauro Bucchi, Fabiola Giudici, Federica Toffolutti, Angela De Paoli, Silvia Mancini, Mario Preti, Gemma Gatta, Stefano Ferretti, Emanuele Crocetti, Anna Rita Fiore, Ettore Bidoli, Adele Caldarella, Fabio Falcini, Alessio Gili, Francesco Cuccaro, Maria Letizia Gambino, Claudia Casella, Rossella Cavallo, Margherita Ferrante, Enrica Migliore, Giuliano Carrozzi, Antonino Musolino, Walter Mazzucco, Cinzia Gasparotti, Mario Fusco, Paola Ballotari, Giuseppe Sampietro, Lucia Mangone, William Mantovani, Giuseppe Cascone, Michael Mian, Federica Manzoni, Maria Teresa Pesce, Rocco Galasso, Francesca Bella, Pietro Seghini, Anna Clara Fanetti, Daniela Piras, Pasquala Pinna, Diego Serraino, Stefano Guzzinati, Luigino Dal Maso","doi":"10.1016/j.ejso.2024.108707","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Five-year net survival and conditional survival from vulvar squamous cell carcinoma (VSCC) patients in Italy have shown no progress during the past three decades. This study aims to estimate the complete prevalence and multiple indicators of cure.</p><p><strong>Methods: </strong>Observed prevalence was estimated using 31 Italian cancer registries covering 47 % of Italian women. A subset of 22 cancer registries was used to estimate model-based long-term survival and indicators of cure, i.e., complete prevalence, cure fraction (CF), time to cure (TTC), proportion of 'already cured' patients, and cure prevalence.</p><p><strong>Results: </strong>In 2018, VSCC patients alive in Italy (complete prevalence) were 6620 or 22 per 100,000 women. The cure fraction (the proportion of newly diagnosed patients who will not die of VSCC) did not change between 2000 and 2010 both for all patients (32 %) and in each age group. The time to cure (5-year conditional net survival >95 %) was 11 years for patients aged ≥44 years, but excess mortality remained for >15 years in the other age groups. This led to a negligible (5 %) proportion of 'already cured' patients (living longer than time to cure). The proportion of patients alive <2 years (21 %) was the same as that of patients surviving ≥15 years. The cure prevalence (patients who will not die of VSCC) was 64 %. A considerable proportion of patients will not be cured even among those who survived ≥5 years.</p><p><strong>Conclusion: </strong>There is an urgent need to reshape the current vulvar care model in Italy.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejso","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejso.2024.108707","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Five-year net survival and conditional survival from vulvar squamous cell carcinoma (VSCC) patients in Italy have shown no progress during the past three decades. This study aims to estimate the complete prevalence and multiple indicators of cure.
Methods: Observed prevalence was estimated using 31 Italian cancer registries covering 47 % of Italian women. A subset of 22 cancer registries was used to estimate model-based long-term survival and indicators of cure, i.e., complete prevalence, cure fraction (CF), time to cure (TTC), proportion of 'already cured' patients, and cure prevalence.
Results: In 2018, VSCC patients alive in Italy (complete prevalence) were 6620 or 22 per 100,000 women. The cure fraction (the proportion of newly diagnosed patients who will not die of VSCC) did not change between 2000 and 2010 both for all patients (32 %) and in each age group. The time to cure (5-year conditional net survival >95 %) was 11 years for patients aged ≥44 years, but excess mortality remained for >15 years in the other age groups. This led to a negligible (5 %) proportion of 'already cured' patients (living longer than time to cure). The proportion of patients alive <2 years (21 %) was the same as that of patients surviving ≥15 years. The cure prevalence (patients who will not die of VSCC) was 64 %. A considerable proportion of patients will not be cured even among those who survived ≥5 years.
Conclusion: There is an urgent need to reshape the current vulvar care model in Italy.
期刊介绍：
JSO - European Journal of Surgical Oncology ("the Journal of Cancer Surgery") is the Official Journal of the European Society of Surgical Oncology and BASO ~ the Association for Cancer Surgery.
The EJSO aims to advance surgical oncology research and practice through the publication of original research articles, review articles, editorials, debates and correspondence.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
